Objective:To explore the molecular mechanism of the prescription for the syndrome of cold-damp-ness obstructing the lung in the treatment of corona virus disease 2019(COVID-19).Methods:The medicinals for the treatment...Objective:To explore the molecular mechanism of the prescription for the syndrome of cold-damp-ness obstructing the lung in the treatment of corona virus disease 2019(COVID-19).Methods:The medicinals for the treatment of the syndrome of cold-dampness obstructing the lung,such as Cangzhu(Rhizoma Atractylo-dis),Chenpi(Pericarpium Gitri Reticulatae),Houpo(Cortex Magnoliae Officinalis),Huoxiang(Herba Agastachis),Caoguo(Fructus Tsaoko),Mahuang(Herba Ephedrae),Qianghuo(Rhizoma et Radix Notoptery-gi),Shengjiang(Rhizoma Zingiberis Recens),Binlang(Semen Arecae)in the Diagnosis and Treatment Pro-gram of COVID-19(Trial Version 6)were taken as research subjects,and the combination of these nine me-dicinals can be called Hanshi Zufei Fang(寒湿阻肺方,HSZFF).The active components and targets of each single Chinese materia medica was screened and obtained through the Traditional Chinese Medicine Systems Pharmacology(TCMSP)database.The target information related to COVID-19 was retrieved through the Gene-Cards disease-related target database.The medicinal prediction targets were mapped to the disease target to ob-tain the intersection targets.The DAVID database was applied to perform gene ontology(GO)enrichment anal-ysis and kyoto encyclopedia of genes and genomes(KEGG)pathway analysis on the targets;GraphPad Prism 5.0 software was applied to plot the biological process(BP)of GO enrichment analysis,cellular component(CC),molecular function(MF)histograms;OmicShare online software was applied to make KEGG advanced bubble chart;Cytoscape software was applied to visualize the interaction with the targets and Chinese materia medica-components-targets results.Results:Totally 56 key active components of 9 Chinese materia medica for cold-dampness obstructing lung syndrome were screened,and 55 targets were obtained.The results of GO and KEGG enrichment analysis showed that the compound prescription mainly regulated the body's immune re-sponse and reduced inflammation by regulating such signaling pathways of inflammatory response and immune regulation as TNF signaling pathway,HIF-1 signaling pathway,Toll-like receptor signaling pathway,infuenza A signaling pathway,T cell receptor signaling pathway.Conclusion:HSZFF can eliminate infl ammation and inhibit virus by regulating immune inflammatory factors closely related to the occurrence and development of diseases through multi-component and multi-target.展开更多
Objective： To study the efficacy of modified Wuzhuyu Decoction Granule （加减吴茱萸汤颗粒剂, MWDG） in the treatment of migraine patients with cold and stasis obstructing meridian syndrome. Methods： This study was a...Objective： To study the efficacy of modified Wuzhuyu Decoction Granule （加减吴茱萸汤颗粒剂, MWDG） in the treatment of migraine patients with cold and stasis obstructing meridian syndrome. Methods： This study was a randomized, double-blind, placebo-controlled trial. A total of 78 migraine patients with cold and stasis obstructing meridian syndrome were recruited and randomly assigned by a ratio of 2：1 into a treatment group （51 cases） and a placebo group （27 cases）. Patients in the treatment group were treated with MWDG while placebo granules were applied in the control group. The treatment course lasted for 12 weeks with a follow-up of 4 weeks. The primary outcome measures included frequency and days of migraine attacks and the secondary outcome measures were analgesics consumption and visual analogue scale （VAS） scores. All outcome assessments were conducted respectively at baseline, the 4th, 8th and 12th week, and the end of follow-up. Results： In the treatment group, significant decrease in frequency of migraine attacks were observed since the 4th week and that of analgesics consumption since the 8th week （both P〈0.05）. While, in the placebo group, significant decrease in frequency of migraine attacks were observed since the 8th week and that of analgesics consumption since the 12th week （both P〈0.05）. No significant decrease in days of migraine attacks and VAS scores of migraine pain were observed in both groups. Between the two groups, there were significant differences in VAS scores and intensity of pain appeared in the 8th week （P〈0.05）. However, no significant differences were found in days and frequency of migraine attacks and analgesics consumption （P〉0.05）. Conclusions： MWDG was probably effective in the treatment of migraine especially for alleviating pain intensity. Furthermore, MWDG could reduce the frequency of migraine attacks and analgesics consumption sooner than the placebo.展开更多
目的:观察不同频次铜砭循经刮痧对痰浊阻肺型肺胀患者肺功能的影响。方法:选取台州市中医院2022年7月至2023年7月诊治的痰浊阻肺型肺胀患者144例,按随机数字表法分为常规组、观察1组和观察2组,每组各48例。常规组给予常规西医治疗,观察...目的:观察不同频次铜砭循经刮痧对痰浊阻肺型肺胀患者肺功能的影响。方法:选取台州市中医院2022年7月至2023年7月诊治的痰浊阻肺型肺胀患者144例,按随机数字表法分为常规组、观察1组和观察2组,每组各48例。常规组给予常规西医治疗,观察1组在常规组治疗的基础上加用铜砭循经刮痧治疗,每周1次,观察2组在常规组治疗的基础上加用铜砭循经刮痧治疗,具体操作方法同观察1组,变更刮痧频次为每周2次。观察3组患者治疗前后生活质量[慢性阻塞性肺疾病评估测试(COPD Assessment test,CAT)]、中医证候积分、肺功能[第1秒用力呼吸容积(Forced expiratory volume in one second,FEV1)和第1秒用力呼吸容积占用力肺活量之比值(percentage of forced expiratory volume in first second to forced vital capacity,FEV1/FVC)]、6min步行距离试验(6 minute walking distance,6MWD)变化情况及不良反应发生情况。结果:3组治疗后CAT评分、中医证候积分均低于治疗前,且观察1组治疗后CAT评分、中医证候积分低于常规组,观察2组CAT评分、中医证候积分低于观察1组、常规组,差异有统计学意义(P<0.05)。3组治疗后FEV1、FEV1/FVC、6MWD均高于治疗前,且观察1组FEV1、FEV1/FVC、6MWD高于常规组,观察2组FEV1、FEV1/FVC、6MWD高于观察1组、常规组,差异有统计学意义(P<0.05)。3组患者治疗期间均未出现明显不良反应。结论:痰浊阻肺型肺胀患者采用铜砭循经刮痧治疗均有效,每周2次的铜砭循经刮痧治疗方案效果优于每周1次的治疗方案,可缓解患者临床症状,改善其肺功能和生活质量,且安全性良好。展开更多
基金We thank for the funding support from the National Natural Science Foundation of China(81873285)。
文摘Objective:To explore the molecular mechanism of the prescription for the syndrome of cold-damp-ness obstructing the lung in the treatment of corona virus disease 2019(COVID-19).Methods:The medicinals for the treatment of the syndrome of cold-dampness obstructing the lung,such as Cangzhu(Rhizoma Atractylo-dis),Chenpi(Pericarpium Gitri Reticulatae),Houpo(Cortex Magnoliae Officinalis),Huoxiang(Herba Agastachis),Caoguo(Fructus Tsaoko),Mahuang(Herba Ephedrae),Qianghuo(Rhizoma et Radix Notoptery-gi),Shengjiang(Rhizoma Zingiberis Recens),Binlang(Semen Arecae)in the Diagnosis and Treatment Pro-gram of COVID-19(Trial Version 6)were taken as research subjects,and the combination of these nine me-dicinals can be called Hanshi Zufei Fang(寒湿阻肺方,HSZFF).The active components and targets of each single Chinese materia medica was screened and obtained through the Traditional Chinese Medicine Systems Pharmacology(TCMSP)database.The target information related to COVID-19 was retrieved through the Gene-Cards disease-related target database.The medicinal prediction targets were mapped to the disease target to ob-tain the intersection targets.The DAVID database was applied to perform gene ontology(GO)enrichment anal-ysis and kyoto encyclopedia of genes and genomes(KEGG)pathway analysis on the targets;GraphPad Prism 5.0 software was applied to plot the biological process(BP)of GO enrichment analysis,cellular component(CC),molecular function(MF)histograms;OmicShare online software was applied to make KEGG advanced bubble chart;Cytoscape software was applied to visualize the interaction with the targets and Chinese materia medica-components-targets results.Results:Totally 56 key active components of 9 Chinese materia medica for cold-dampness obstructing lung syndrome were screened,and 55 targets were obtained.The results of GO and KEGG enrichment analysis showed that the compound prescription mainly regulated the body's immune re-sponse and reduced inflammation by regulating such signaling pathways of inflammatory response and immune regulation as TNF signaling pathway,HIF-1 signaling pathway,Toll-like receptor signaling pathway,infuenza A signaling pathway,T cell receptor signaling pathway.Conclusion:HSZFF can eliminate infl ammation and inhibit virus by regulating immune inflammatory factors closely related to the occurrence and development of diseases through multi-component and multi-target.
基金Supported by the "Eleventh Five-Year Plan" of China State Science&Technology Ministry(No.2007BAI20B053)National Natural Science Foundation of China(No.81273688)
文摘Objective： To study the efficacy of modified Wuzhuyu Decoction Granule （加减吴茱萸汤颗粒剂, MWDG） in the treatment of migraine patients with cold and stasis obstructing meridian syndrome. Methods： This study was a randomized, double-blind, placebo-controlled trial. A total of 78 migraine patients with cold and stasis obstructing meridian syndrome were recruited and randomly assigned by a ratio of 2：1 into a treatment group （51 cases） and a placebo group （27 cases）. Patients in the treatment group were treated with MWDG while placebo granules were applied in the control group. The treatment course lasted for 12 weeks with a follow-up of 4 weeks. The primary outcome measures included frequency and days of migraine attacks and the secondary outcome measures were analgesics consumption and visual analogue scale （VAS） scores. All outcome assessments were conducted respectively at baseline, the 4th, 8th and 12th week, and the end of follow-up. Results： In the treatment group, significant decrease in frequency of migraine attacks were observed since the 4th week and that of analgesics consumption since the 8th week （both P〈0.05）. While, in the placebo group, significant decrease in frequency of migraine attacks were observed since the 8th week and that of analgesics consumption since the 12th week （both P〈0.05）. No significant decrease in days of migraine attacks and VAS scores of migraine pain were observed in both groups. Between the two groups, there were significant differences in VAS scores and intensity of pain appeared in the 8th week （P〈0.05）. However, no significant differences were found in days and frequency of migraine attacks and analgesics consumption （P〉0.05）. Conclusions： MWDG was probably effective in the treatment of migraine especially for alleviating pain intensity. Furthermore, MWDG could reduce the frequency of migraine attacks and analgesics consumption sooner than the placebo.
文摘目的:观察不同频次铜砭循经刮痧对痰浊阻肺型肺胀患者肺功能的影响。方法:选取台州市中医院2022年7月至2023年7月诊治的痰浊阻肺型肺胀患者144例,按随机数字表法分为常规组、观察1组和观察2组,每组各48例。常规组给予常规西医治疗,观察1组在常规组治疗的基础上加用铜砭循经刮痧治疗,每周1次,观察2组在常规组治疗的基础上加用铜砭循经刮痧治疗,具体操作方法同观察1组,变更刮痧频次为每周2次。观察3组患者治疗前后生活质量[慢性阻塞性肺疾病评估测试(COPD Assessment test,CAT)]、中医证候积分、肺功能[第1秒用力呼吸容积(Forced expiratory volume in one second,FEV1)和第1秒用力呼吸容积占用力肺活量之比值(percentage of forced expiratory volume in first second to forced vital capacity,FEV1/FVC)]、6min步行距离试验(6 minute walking distance,6MWD)变化情况及不良反应发生情况。结果:3组治疗后CAT评分、中医证候积分均低于治疗前,且观察1组治疗后CAT评分、中医证候积分低于常规组,观察2组CAT评分、中医证候积分低于观察1组、常规组,差异有统计学意义(P<0.05)。3组治疗后FEV1、FEV1/FVC、6MWD均高于治疗前,且观察1组FEV1、FEV1/FVC、6MWD高于常规组,观察2组FEV1、FEV1/FVC、6MWD高于观察1组、常规组,差异有统计学意义(P<0.05)。3组患者治疗期间均未出现明显不良反应。结论:痰浊阻肺型肺胀患者采用铜砭循经刮痧治疗均有效,每周2次的铜砭循经刮痧治疗方案效果优于每周1次的治疗方案,可缓解患者临床症状,改善其肺功能和生活质量,且安全性良好。
